Abstracts

764 – Switching to DTG/3TC vs BIC/FTC/TAF and Steatotic Liver Disease: A Substudy of PASODOBLE Trial

Background Steatotic liver disease (SLD) is a common condition in PLWH, linked to overweight and associated metabolic disorders. Both INSTIs and TAF have been associated with weight gain in clinical trials and real-life studies. Likewise, TAF has also been associated with SLD. Controversial results have been reported regarding INSTIs and SLD. In virologically suppressed PLWH,…

747 – Predictors of HIV Drug Resistance to Dolutegravir in 4 PEPFAR-Supported Countries

Background Dolutegravir-based regimens (DBR) represent >92% of drugs dispensed in PEPFAR-supported programs. Monitoring emergence of and characterizing the risk factors for dolutegravir (DTG) drug resistance (DR) acquisition is a key priority to ensure the continued efficacy and durability of these regimens. We report risk factors for DTG DR identified in a large cohort of patients…

723 – The Barrier to Escape From Broadly Neutralizing Antibodies Varies Between Different HIV-1 Isolates

Background Broadly neutralizing antibodies (bNAbs) against HIV-1 have re-invigorated research into antibody therapies and vaccination strategies for prevention, treatment, and cure of HIV-1 because of their unique ability to neutralize diverse HIV-1 strains. While many HIV-1 isolates are initially susceptible to bNAbs, their ability to acquire resistance is unknown. Understanding the evolutionary barriers to bNAb…

727 – Modifying PF74 Improves Anti-HIV-1 Activity Against the Resistance-Associated Capsid Mutation N74D

Background Lenacapavir (LEN) is an FDA-approved drug for highly treatment-experienced individuals living with multidrug-resistant HIV-1 infection. LEN inhibits HIV-1 replication with sub-nanomolar potency by targeting the capsid protein (CA) at the “FG-binding pocket” (FGBP). Clinical trials report the emergence of CA mutations like M66I and N74D after LEN treatment. N74D is also selected by PF74,…

733 – Molecular Epidemiology of HIV-1 Transmitted Drug Resistance Among Subtypes Circulating in Italy

Background The aim of this study was to characterize subtypes circulation and transmitted drug resistance (TDR) in Italy by next-generation sequencing (NGS). Methods Routine plasma HIV-1 RNA NGS genotyping data were collected from newly diagnosed individuals over 2021-2024. TDR for PI, NRTI, NNRTI and INI, and genotypic susceptibility were evaluated through HIVdb (ver.9.6) with NGS…

741 – Impact of Resistance to Antiretroviral Therapy Among Veterans With Human Immunodeficiency Virus

Background Despite significant progress made in antiretroviral (ARV) therapy for human immunodeficiency virus-1 (HIV-1) treatment, one of the major challenges facing the efficacy of ARV is drug resistance. The objective of this study was to evaluate clinical outcomes associated with resistance to ARV among people with HIV (PWH).  Methods This national retrospective cohort study was…

724 – In Vitro Resistance Profile for GS-1720, a Potent Once-Weekly Oral InSTI in Clinical Development

Background Integrase strand transfer inhibitors (INSTIs) are the cornerstone of current HIV therapies, but their oral dosing remains limited to once-daily administration. Herein we describe the in vitro resistance profile for GS-1720, a potent and selective investigational INSTI with Phase 1 clinical pharmacokinetic, safety and antiviral efficacy data supportive of once-weekly oral dosing. Methods GS-1720…

770 – Hepatitis B Reactivation in PWH With Isolated Anti-Core Pattern on Therapies Excluding Tenofovir

Background The isolated anti-core pattern (antiHBc+, antiHBs-, HBsAg-) is more frequently observed in people living with HIV (PWH). It suggests a past hepatitis B virus (HBV) infection; however, it can also indicate an occult HBV infection, which implicates a risk of viral reactivation. Historically, antiretroviral (ART) regimens containing tenofovir (TXF) have effectively suppressed HBV replication,…

702 – A Multicenter Study of Albuvirtide Combined With 3BNC117 in Multidrug-Resistant HIV-1 Infection

Background For some individuals with HIV-1 infection who have failed multiple antiretroviral regimens and have limited treatment options, there is an urgent need for new antiretroviral drugs with novel mechanisms of action. Albuvirtide (ABT) is an HIV-1 fusion inhibitor and 3BNC117 is an HIV-specific, broadly neutralizing monoclonal antibody. We aimed to assess the efficacy and safety…